European Journal of Neurology

  • european-journal-neurologyMar. 1, 2011, European Journal of Neurology

    Alena Novotna, MD, et al., stated the following in their Mar. 1, 2011 study titled “A Randomized, Double-blind, Placebo-controlled, Parallel-group, Enriched-design Study of Nabiximols (Sativex), as Add-on Therapy, in Subjects with Refractory Spasticity Caused by Multiple Sclerosis,” published in the European Journal of Neurology:

    “Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. Subjects were treated with nabiximols [Sativex], as add-on therapy, in a single-blind manner… This study has shown Sativex to improve spasticity in patients who had failed to respond adequately to other antispasticity medications…”

  • Tags: ,
  • Comments